skip to navigation

Tunnel Vision-The Economic Impact of Primary Open Angle Glaucoma

Authored by Access Economics
Posted on July 19, 2011
Topic: Advocacy/Vision 2020, Journal/Publication
Not yet rated

PDF (4 MB)    Download »

Analyzes the economic impact of primary open angle glaucoma (POAG). In support of this, the report provides a dynamic model of POAG in Australia that encompassed prevalence, incidence, risk factors, health and indirect financial costs, treatment options and measures of well being.

Access Economics Pty Limited was commissioned by the Center for Eye Research Australia to document the model and report on the impacts over the period 2005-2025 of:

< better detection of POAG;
< a change in treatment protocol; and
< a potential new therapy to delay disease progression.

A similar model was previously developed to examine the impact of a number of new treatments modes on age-related macular degeneration: a quit smoking program; new research that delays progression; and a new therapy that enhances treatment efficacy (CERA 2006).

The model has the capacity to be adapted to incorporate other sources of visual impairment in the future, such as diabetic retinopathy, cataract, and refractive error.

This project follows on from earlier reports

  •  Clear Insight: The Economic Impact and Cost of Vision Loss in Australia (CERA 2004);
  • Investing in Sight: Strategic Interventions to Prevent Vision Loss in Australia (CERA 2005); and
  • Centrally Focused: The Impact of Age-related Macular Degeneration, A Dynamic Economic Model (CERA 2006).

Due to the technical nature of the modelling, this report assumes familiarity with the terminology used in these previous reports.

This report is structured as follows:

  • Description of POAG;
  • Epidemiology of the disease (including remission, mortality, progression of the disease when untreated and incidence and prevalence);
  • Treatment of the disease (including a description of the conventional treatment steps, their side effects and efficacy);
  • The costs of the disease (including its impact on quality of life, the health system costs, productivity costs and other indirect costs);
  • Description of the Model, its structure and user interface; and
  • Discussion of the scenarios that the model can be used to analyse.

Stay connected:         Follow us on Instagram

Web site design and web development by D3 Solutions